Enzolytics Inc (ENZC)

[foxi]

Two different products, two different companies.

https://rosettalifecarebg.org/cooperation-between-enzolytics-inc-and-rosetta-lifecare-bulgaria-in-advanced-phase/

We welcome the plans of Enzolytics, Inc. to introduce to the U.S. market its immunomodulator identified by the trademark “Enzolytics IPF Immune.”

Because the Enzolytics product is similar in composition to the immunomodulator offered by Rosetta under the trademark “Enzoimmune Active”, and in order to avoid future misunderstandings or speculation, we consider it necessary to clarify the following: Both products are based on the same biotechnology platform (IPF), patented by the Zhabilov Trust (US Patent No. 8,309,072).

Enzolytics IPF Immune is a trademark of Enzolytics, Inc, intended for distribution in North America. Enzoimmune Active is a trademark of Rosette Lifecare, designed for distribution in Europe, Asia, Africa and South America. Enzoimmune Active is not commercially available in the United States, where Enzolytics IPF Immune will be available in the U.S. soon.

Rosetta and Enzolytics continue their cooperation in establishing their products on the world market.

A tangled web they weave, working together as partners with confusing overlap in product and naming.


Also, nobody seems to know what happened to ENZC's revenue in Q3 2021. They had $200k in licensing revenue in Q2 per this filing (page 2), but $0 revenue in Q3 per this filing (page 2). Will be interesting to see what they put on the next filing.